de
en
de
en
International
About us
BERLIN-CHEMIE
MENARINI Group
Our History
Our Goal
Executive Board
Responsibility
Code of Conduct
Sustainability & social commitment
Code of practice for business partners
Press & Media
News and Press Releases
Media library
Contact
Jobs & Careers
About us
BERLIN-CHEMIE
Manufacturing & Quality assurance
Business Development
MENARINI Group
Our History
Our Goal
Executive Board
Responsibility
Code of Conduct
Sustainability & social commitment
Code of practice for business partners
Press & Media
News and Press Releases
Media library
Contact
Jobs & Careers
Home >>
Contact >>
Purchasing Terms >>
Quality Requirements API / EXC >>
Data Protection Information Notice for Healthcare Professionals >>
Data Protection Information Notice for Patients >>
Privacy >>
Disclaimer >>
Imprint >>
Sitemap >>
Change cookie settings »
Press & Media
|
News and Press Releases
|
News Detail
News and Press Releases
Media library
The Dates of the XXVII Edition of the International Fair Play Menarini Awards
4/14/2023
Read more
Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in
1/30/2023
Read more
Ibuprofen suspension – exemption to safeguard supply of the population
1/2/2023
Read more
Berlin becomes a transfer region for green chemistry
10/6/2022
Read more
BERLIN-CHEMIE celebrates 30 years of affiliation to the MENARINI Group
9/6/2022
Read more
Sport’s finest gather under the stars for the grand finale of the XXVI Fair Play Menarini International Award
7/8/2022
Read more
BERLIN-CHEMIE Menarini‘s Position in der Ukraine
5/9/2022
Read more
Christiane von der Eltz becomes new member of the Executive Board of BERLIN-CHEMIE responsible for the Pharma Germany Division
5/3/2022
Read more
Menarini Receives FDA Orphan Drug Designation for SEL24/MEN1703, a first in class, dual PIM/FLT3 inhibitor for the Treatment of Acute Myeloid Leukemia
11/4/2021
Read more
Menarini Group and Radius Health Announce Positive Phase 3 Topline Results from the EMERALD Trial Evaluating Elacestrant in Breast Cancer
10/20/2021
Read more
1
2
3
4
LAST NEWS
The Dates of the XXVII Edition of the International Fair Play Menarini Awards
4/14/2023
Read more
Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in
1/30/2023
Read more
Ibuprofen suspension – exemption to safeguard supply of the population
1/2/2023
Read more
Berlin becomes a transfer region for green chemistry
10/6/2022
Read more
News archive
Archive
Expand/Collapse
2023
(3)
2023, April
(1)
2023, January
(2)
Expand/Collapse
2022
(5)
2022, October
(1)
2022, September
(1)
2022, July
(1)
2022, May
(2)
Expand/Collapse
2021
(3)
2021, November
(1)
2021, October
(1)
2021, April
(1)
Expand/Collapse
2020
(7)
2020, November
(1)
2020, October
(1)
2020, July
(1)
2020, June
(2)
2020, May
(1)
2020, January
(1)
Expand/Collapse
2019
(1)
2019, September
(1)
Expand/Collapse
2018
(5)
2018, December
(1)
2018, October
(1)
2018, September
(1)
2018, March
(2)
Expand/Collapse
2017
(4)
2017, June
(1)
2017, March
(2)
2017, January
(1)
Expand/Collapse
2016
(6)
2016, December
(2)
2016, November
(1)
2016, October
(1)
2016, May
(1)
2016, March
(1)
Responsibility >>
BERLIN-CHEMIE
International >>
SCROLL TO TOP